Tadalafil 5 mg
Sponsors
Eli Lilly and Company, Yuyu Pharma, Inc., Fayoum University Hospital, Assiut University, Tri-Service General Hospital
Conditions
Benign Prostatic HyperplasiaBenign Prostatic Hyperplasia (BPH)Chemotherapy Induced Peripheral Neuropathy (CIPN)Erectile DysfunctionErectile DysfunctionsNeurotoxicityOveractive Bladder (OAB)Overactive Bladder Syndrome
Phase 1
Phase 2
Study of Tadalafil Once-a-Day for 12 Weeks in Japanese Men With Benign Prostatic Hyperplasia Followed by an Open-Label Extension
CompletedNCT00783094
Start: 2008-11-30End: 2010-04-30Updated: 2011-03-29
o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer
CompletedNCT07333976
Start: 2020-01-05End: 2024-08-13Updated: 2026-01-12
Phase 3
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia
CompletedNCT00970632
Start: 2009-10-31End: 2011-01-31Updated: 2012-03-12
Combination Therapy of Tadalafil 2.5mg Plus Sildenafil 25mg Versus Tadalafil 5 mg Monotherapy for Treatment of Erectile Dysfunction: A Randomized, Placebo-Controlled Double-Blinded Cross-Over Study
Not yet recruitingNCT07177326
Start: 2025-10-01End: 2026-12-01Target: 142Updated: 2025-09-24
Phase 4
Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study
CompletedNCT06947265
Start: 2024-01-14End: 2025-02-01Updated: 2025-04-27
Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study
RecruitingNCT07416968
Start: 2025-09-01End: 2026-12-01Target: 480Updated: 2026-02-18